VIENNA, AUSTRIA AND MONTREAL, CANADA--(Marketwire - May 12, 2008) - PDC Biotech GmbH (PDC) (privately-held) and Theratechnologies (TSX: TH) today announced having entered into an exclusive license agreement for Theratechnologies’ family of antagonists of the prostaglandin F2 alpha receptor for use in preterm labour and primary dysmenorrhea (painful menstruation). In June 2006, Theratechnologies had granted an option to licence PDC31 (formerly Theratechnologies’ THG113.31) which had shown efficacy in vitro and in animal models in pre-term labour. With this exclusive licence PDC will be developing both an injectable formulation for the treatment of preterm labour and a topical formulation of this compound for the treatment of primary dysmenorrhea. The terms of the agreement were not disclosed.
